Grünenthal, a global science-based, privately-owned pharmaceutical company, has announced an agreement with Bayer AG to acquire Nebido, the brand for the treatment of male hypogonadism and its associated brands for up to €500 million.
Nebido is the only long-acting injectable treatment for testosterone deficiency. The product is approved and commercialised in over 80 countries.
The brand is expected to add around €100 million to Grünenthal’s EBITDA in 2023.
The acquisition is subject to customary closing conditions, including approval by the relevant competition authorities. Closing is expected to occur by the end of 2022.
Grünenthal CEO, Gabriel Baertschi, said:
“One in six men over 50 live with the symptoms of testosterone deficiency. Too few of these patients receive appropriate treatment.
“We are committed to facilitating access to treatment for even more patients in need.
“Grünenthal’s strong track record of acquiring established brands has significantly improved our profitability, allowing us to invest in research and development and create the next generation of pain therapies.”
Nebido is used for the treatment of clinical symptoms of male hypogonadism such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction due to low testosterone levels (testosterone deficiency).
The product is directly administered by a physician every 10 – 14 weeks. Nebido demonstrated a robust safety and efficacy profile backed with solid long-term data.
The acquisition of Nebido is part of a series of acquisitions by Grünenthal, including the European rights to CRESTOR and Nexium, the global rights to Vimovo (ex-US and Japan), the global rights to Qutenza and the global rights to ZomigTM (ex-Japan).
In 2021, Grünenthal acquired the Swiss biotech company Mestex AG including its innovative investigational medicine resiniferatoxin for the intra-articular treatment of pain associated with osteoarthritis of the knee.
Grünenthal has invested over € 2 billion in successful M&A transactions over the past years.
